Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology

Area of Science:

• Molecular pathology
• Precision oncology
• Multiomics technologies

Background:

• Integrated diagnostic approaches are advancing precision oncology.
• Multiomics technologies enable simultaneous assessment of genomic, transcriptomic, proteomic, and metabolic states.
• Large consortia like TCGA and CPTAC demonstrate the value of harmonized multiomics.

Purpose of the Study:

• To review the biological and clinical relevance of multiomics integration in cancer.
• To highlight the critical role of multiomics in comprehensive tumor assessment and functional analyses.
• To provide a framework for interpreting integrated molecular diagnostics and addressing implementation challenges.

Main Methods:

• Leveraging multiomics technologies (genomics, transcriptomics, proteomics, metabolomics).
• Integrating multiomics data with conventional pathological evaluation.
• Analyzing data from large-scale international consortia (e.g., TCGA, CPTAC) and clinical trials (e.g., NCI-MATCH).

Main Results:

• Multiomics analyses define tumor subtypes, uncover dependencies, and yield actionable insights.
• Molecular pathology-guided treatment strategies improve clinical outcomes, including progression-free survival.
• Multi-layered molecular interrogation is crucial, as genomics alone is insufficient for optimal targeted therapy.

Conclusions:

• Multiomics integration is essential for comprehensive morpho-molecular tumor assessment.
• Molecularly stratified treatment approaches are increasingly required in routine clinical practice.
• Overcoming methodological and translational challenges is key to broader precision oncology implementation.